Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.39 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 3/20 | 0.32 |
| ▸ | MMP1 | P03956 | 2/20 | 0.32 |
| ▸ | MMP3 | P08254 | 2/20 | 0.32 |
| ▸ | MMP8 | P22894 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1313929 | 0.97 | — | — | |
| SCHEMBL1314042 | 0.95 | MEN1 (0.50) | MEN1LMNAHPGDTSHRBLM | |
| SCHEMBL1313260 | 0.95 | MEN1 (0.50) | MEN1LMNAHPGDTSHRBLM | |
| SCHEMBL2568760 | 0.80 | LMNA (0.65) | MEN1LMNAHPGDTSHRBLM | |
| SCHEMBL1313487 | 0.77 | LMNA (0.48) | MEN1LMNAHPGDTSHRBLM | |
| SCHEMBL19809602 | 0.76 | GABBR2 (0.50) | GABBR2GABBR1USP2MMP2MMP1 | |
| SCHEMBL29674365 | 0.76 | — | — | |
| SCHEMBL30000468 | 0.76 | GABBR2 (0.50) | MEN1LMNAHPGDTSHRBLM | |
| SCHEMBL19895692 | 0.76 | — | — | |
| SCHEMBL19809600 | 0.76 | GABBR2 (0.50) | GABBR2GABBR1USP2MMP2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085734-B2 | Process for preparing mono-carboxy-functionalized dialkylphosphinic acids, esters and salts by means of alkylene oxides and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-07-21 | — | — | US | disclosed |
| US-8987489-B2 | Method for producing mono-carboxy-functionalized dialkylphosphinic acids, esters and salts using a vinyl ether and the use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-03-24 | — | — | US | disclosed |
| US-8735476-B2 | Method for producing mono-carboxy-functionalized dialkylphosphinic acids, esters and salts using a vinyl ester of a carboxylic acid and the use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2014-05-27 | — | — | US | disclosed |
| US-20110275744-A1 | Method for Producing Mono-Carboxy-Functionalized Dialkylphosphinic Acids, Esters and Salts Using a Vinyl Ether and the Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-11-10 | — | — | US | disclosed |
| US-20110245385-A1 | Process for Preparing Mono-Carboxy-Functionalized Dialkylphosphinic Acids, Esters and Salts by Means of Alkylene Oxides and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-10-06 | — | — | US | disclosed |
| US-20110237721-A1 | Method for Producing Mono-Carboxy-Functionalized Dialkylphosphinic Acids, Esters and Salts Using a Vinyl Ester of a Carboxylic Acid and the Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237721-A1 | Method for Producing Mono-Carboxy-Functionalized Dialkylphosphinic Acids, Esters and Salts Using a Vinyl Ester of a Carboxylic Acid and the Use Thereof | SCO2, HAO2, DAO | MEN1 3632/4885LMNA 2720/4885HPGD 2298/4885 |
| US-20110245385-A1 | Process for Preparing Mono-Carboxy-Functionalized Dialkylphosphinic Acids, Esters and Salts by Means of Alkylene Oxides and Use Thereof | AGL, ACSL3, MGLL | MEN1 2287/4885LMNA 2532/4885HPGD 3719/4885 |
| US-20110275744-A1 | Method for Producing Mono-Carboxy-Functionalized Dialkylphosphinic Acids, Esters and Salts Using a Vinyl Ether and the Use Thereof | SCO2, HAO2, ACSL3 | MEN1 3216/4885LMNA 3557/4885HPGD 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.